CXCL8 and cancer: An anti-CXCL8 neutralizing antibody BMS-986253, when combined with nivolumab, showed tolerable safety and resulted in partial response (PR) in cancer patients who had previously progressed after anti-PD-(L)1 or anti-CTLA-4 treatment [365].